Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (173)	5/31/2001 11:04:55 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 1022

George, It's circumstantial evidence to be sure, but since Richard Lerner is at Scripps and is one of the founders of the phage technology acquired by alxn (and remains an adviser to the company), and the Scripps (Lerner)/Winters patents are at the core of many if not most phage licenses, then I think you could say one of the true "thought leaders" believes xoma's technology is essential for phage processes. Of course, we don't know if the alxn license is somehow conditioned on subsequent events, like litigation. The IP in phage is truly a bramblebush, based on the alxn license and Lerner's involvement, it looks to me like xoma has a ring-side seat. If by 'market' you mean the total downstream therapeutic market for biologic pharmaceuticals and assays, then it is as big as it can be. The first fully human Mab approved for human use is likely to be phage derived (D2e7), and there are hundreds coming behind. How many different ways the money will be divided and what will be left as royalties for the enabling phage patent holders is unfathomable, and may be like what is left of the Colorado by the time it enters the Gulf of California. Dyax claims to be at the headwaters of phage patents, and they may be, so if you want a comparable of "pure" license potential (it's not pure), it may be your answer for the value of a licensor. But like all the others, DYAX is going to have to do drugs to reach their finacial goals. If you come up with a better answer I'd love to hear it! FWIW, Wilder

To: aknahow who wrote (173)	6/2/2001 2:41:37 PM
From: nigel bates	Read Replies (2) \| Respond to of 1022

No, not that Are you sure ? On Tuesday, March 20, 2001, the U.S. Patent Office issued Patent No. 6,204,023, "Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use". The claims are directed to processes for preparing immunoglobulins that are secreted from bacteria and are capable of antigen binding. This is the sixth patent issued to XOMA in its antibody expression family of patents and the third patent in this family that broadly covers methods for the secretion of functional immunoglobulins from bacteria, including single-chain antibodies and antibody fragments. Bacterial antibody expression is a key enabling technology for the discovery and selection, as well as the development and manufacture, of many recombinant antibody-based pharmaceuticals. Antibody discovery by phage display technology, for example, depends upon expressing antibody domains in bacteria as properly folded, functional, secreted proteins, as described in XOMA's patent claims.